Free Trial

Editas Medicine (EDIT) News Today

Editas Medicine logo
$1.54 -0.10 (-6.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.54 -0.01 (-0.32%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Editas Medicine, Inc. stock logo
Zacks Research Raises Earnings Estimates for Editas Medicine
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research increased their FY2027 EPS estimates for Editas Medicine in a research report issued to clients and investors on Tuesday, April 29th. Zacks Research analyst A. Chakraborty now expects that the company will earn (
FY2027 EPS Estimates for Editas Medicine Raised by Analyst
Editas Medicine, Inc. stock logo
Analysts Offer Predictions for Editas Medicine Q1 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Editas Medicine in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($0.55) per
Editas Medicine, Inc. stock logo
Editas Medicine (NASDAQ:EDIT) Upgraded by Cantor Fitzgerald to Strong-Buy Rating
Cantor Fitzgerald upgraded Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday.
Editas Medicine (NASDAQ:EDIT) Upgraded at Cantor Fitzgerald
HC Wainwright Estimates Editas Medicine Q1 Earnings
Editas Medicine, Inc. stock logo
HC Wainwright Upgrades Editas Medicine (NASDAQ:EDIT) to Strong-Buy
HC Wainwright raised Editas Medicine to a "strong-buy" rating in a report on Monday.
Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from Analysts
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has earned a consensus rating of "Hold" from the fourteen ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating
Editas Medicine, Inc. stock logo
Renaissance Technologies LLC Acquires Shares of 1,451,049 Editas Medicine, Inc. (NASDAQ:EDIT)
Renaissance Technologies LLC bought a new position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,451,049 shares of the company's stock, valued at approximately $1,843,000. Re
Editas Medicine, Inc. stock logo
Leerink Partnrs Predicts Editas Medicine Q3 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Leerink Partnrs issued their Q3 2025 earnings per share estimates for Editas Medicine in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings per share of ($0.14) for
Editas Medicine, Inc. stock logo
Leerink Partnrs Forecasts Editas Medicine Q1 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Editas Medicine in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($0.46) for the
Editas Medicine, Inc. stock logo
238,967 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Raymond James Financial Inc.
Raymond James Financial Inc. purchased a new stake in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 238,967 shares of the company's stock, valued at approximately $303,00
Editas Medicine: Do The Risks Outweigh The Rewards?
Editas Medicine, Inc. stock logo
Zacks Research Comments on Editas Medicine FY2027 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Editas Medicine in a note issued to investors on Wednesday, March 26th. Zacks Research analyst A. Chakraborty expects that the company will post earn
Editas Medicine, Inc. stock logo
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below 50 Day Moving Average - Here's Why
Editas Medicine (NASDAQ:EDIT) Stock Price Passes Below 50-Day Moving Average - Time to Sell?
Editas Medicine CFO Erick Lucera to step down, Amy Parison to succeed
Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Sees Large Decrease in Short Interest
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 13,770,000 shares, a decline of 21.0% from the February 13th total of 17,440,000 shares. Currently, 17.0% of the company's stock are short sold. Based on an average daily volume of 4,140,000 shares, the days-to-cover ratio is currently 3.3 days.
Editas Medicine, Inc. stock logo
Monaco Asset Management SAM Buys Shares of 1,069,732 Editas Medicine, Inc. (NASDAQ:EDIT)
Monaco Asset Management SAM bought a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,069,732 shares of
Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by Analysts
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been assigned an average rating of "Hold" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three
Editas Medicine (EDIT) Gets a Buy from Evercore ISI
Editas Medicine, Inc. stock logo
Editas Medicine (NASDAQ:EDIT) Announces Earnings Results
Editas Medicine (NASDAQ:EDIT - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%.
Editas Medicine, Inc. stock logo
Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results
Editas Medicine (NASDAQ:EDIT - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%.
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Editas Medicine, Inc. stock logo
Editas Medicine (EDIT) to Release Earnings on Wednesday
Editas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, February 26.
Editas Medicine, Inc. stock logo
Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday
Editas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, February 26.
Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received an average recommendation of "Hold" from the fourteen ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, nine have issued a hold recomme
Editas Medicine, Inc. stock logo
Editas Medicine (NASDAQ:EDIT) Stock Passes Below 200-Day Moving Average - Here's What Happened
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below Two Hundred Day Moving Average - Here's Why
Editas Medicine, Inc. stock logo
Editas Medicine, Inc. (NASDAQ:EDIT) Sees Significant Growth in Short Interest
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 18,210,000 shares, an increase of 7.6% from the December 31st total of 16,930,000 shares. Based on an average daily volume of 2,620,000 shares, the short-interest ratio is currently 7.0 days.
Chardan Capital downgrades CARGO Therapeutics, Inc. (CRGX) to a Hold
Editas Medicine, Inc. stock logo
Leerink Partnrs Weighs in on Editas Medicine FY2025 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Editas Medicine in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the compan
Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

EDIT Media Mentions By Week

EDIT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EDIT
News Sentiment

0.81

0.72

Average
Medical
News Sentiment

EDIT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EDIT Articles
This Week

20

5

EDIT Articles
Average Week

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:EDIT) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners